Skip to Content
Merck
  • Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride.

Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine (2003-02-08)
Iris Ben-David, Yulia Rozen, Giuseppina Ortu, Eyal Mishani
ABSTRACT

An automated procedure for the radiosynthesis of the labeling synthon [11C]acryloyl chloride was developed and applied for labeling several N-acryl amides with carbon-11. [11C]-6-acrylamido-4-(3,4-dichloro-6-fluoroanilino)quinazoline (ML03), a novel PET biomarker targeting the epidermal growth factor receptor tyrosine kinase (EGFr-TK) in cancer, was successfully prepared using this labeled synthon in a fully automated manner. Two other potential anticancer drugs were also labeled using the developed methodology. The potency of ML03 to inhibit autophosphorylation of EGFr-TK was evaluated by an ELISA assay indicating a low IC(50) of 0.037nM.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Acryloyl chloride, 97.0%, contains <210 ppm MEHQ as stabilizer
Sigma-Aldrich
Acryloyl chloride, ≥97%, contains ~400 ppm phenothiazine as stabilizer